Article Figures & Data
Figures
- Figure 1.
Levels of PSA (A), ααCTX (B) and (C) tALP in prostate cancer patients (PCa) without bone metastases stratified by +N and N0 and controls. Asterisks indicate significant difference between the two groups; ns, not significant different between the two groups.
- Figure 2.
Levels of PSA (A), ααCTX (B), and tALP (C) in prostate cancer patients with (+BM) or without (−BM) bone metastases at each visit. Asterisks indicate significant decrease in the level of each marker in patients +BM compared with baseline.
- Figure 3.
Immunohistochemistry on pelvic lymph node biopsies from six prostate cancer patients. A and B, lymph node–negative adjacent sections; C and D, lymph node positive. A and C, pan-cytokeratin staining (KL1); B and D, αCTX CTX staining (F44). Magnification, ×10 (A-D).
- Figure 4.
Immunohistochemistry and histology on bone tumor tissue secondary from six primary prostate cancer patients. A, pan-cytokeratin (CK-MNF); B, tartrate-resistant acid phosphatase–positive staining of osteoclasts; C, αCTX CTX staining (F44); D, control (adjacent sections). Magnification, ×10 (A-D).
Tables
- Table 1.
Demographic data on controls and prostate cancer patients stratified by ±lymph node metastases
Group Controls PCa N0 PCa N1 n 68 146 24 Mean age (range), y 62.8 (48-77) 65.5 (46-71)ns 62.6 (21-79)ns T stage (pct) — 2 (81), 3 (18), 4 (1) 2 (25), 3 (67), 4 (8) Gleason score (pct) — 4 (4), 5(62), 6(16), 7(16), 8(2) 5 (16), 6 (21), 7 (42), 8 (8), 9 (13) NOTE: N0, lymph node negative; N1, lymph node metastases; T-stage, tumor node metastasis; pct, percentage of total number of patients.
Abbreviations: PCa, prostate cancer; ns, not significant different from control.
- Table 2.
Marker values on prostate cancer patients stratified by ±bone metastases and visit from the treatment study
BM Visit 0 1 2 3 4 ααCTX (μg/mmol; ±SD) − 0.25 (0.17-0.19) 0.23 (0.18-0.22)ns 0.21 (0.18-0.23)ns 0.23 (0.17-0.20)ns 0.24 (0.18-0.21)ns + 0.89 (0.64-0.79) 0.43 (0.25-0.29)** 0.35 (0.23-0.27)* 0.31 (0.20-0.25)* 0.33 (0.19-0.22)** tALP (units/L; ±SD) − 89 (54-62) 76 (39-45)ns 70 (35-40)ns 76 (60-73)ns 73 (38-43)ns + 246 (178-221) 185 (142-178)ns 125 (92-115)*** 111 (78-95)** 120 (65-76)** PSA (μg/L; ±SD) − 96 (170-263) 120 (189-263)* 115 (201-329)* 56 (133-285)** 44 (94-177)** + 115 (142-212) 119 (141-205)** 74 (109-179)** 34 (57-103)** 45 (67-111)*** Asterisks: Significant difference between PCa + BM or PCa − BM compared to baseline.
Volume 17, Issue 5
